Impact of mutations in highly conserved amino acids of the HIV-1 Gag-p24 and Env-gp120 proteins on viral replication in different genetic backgrounds

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Liu, Yi ^a   Rao, Ushnal ^a   McClure, Jan ^a   Konopa, Philip ^a   Manocheewa, Siriphan ^a   Kim, Moon ^a   Chen, Lennie ^a   Troyer, Ryan M ^b,d   Tebit, Denis M ^b   Holte, Sarah ^c   Arts, Eric J ^b   Mullins, James I ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c USA   (United States)

^d Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; GAG P24 PROTEIN; GAG PROTEIN; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; GENE MUTATION; GENE SEQUENCE; GENOMIC FRAGMENT; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 SYBTYPE B; NONHUMAN; VIROGENESIS; VIRUS MORPHOLOGY; VIRUS REPLICATION; AMINO ACID SEQUENCE; CHEMISTRY; GENETICS; HUMAN; MOLECULAR GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; REPRODUCTIVE FITNESS; SEQUENCE ALIGNMENT;

AMINO ACID SEQUENCE; CONSERVED SEQUENCE; GENETIC FITNESS; HIV CORE PROTEIN P24; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; SEQUENCE ALIGNMENT; VIRUS REPLICATION;

EID: 84899434989     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0094240     Document Type: Article

References (42)

1. Gilbert PB, Peterson ML, Follmann D, Hudgens MG, Francis DP, et al. (2005) Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis 191: 666-677. (Pubitemid 40271053)
2. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, et al. (2006) Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 194: 1661-1671. (Pubitemid 44901996)
3. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, et al. (2005) Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 191: 654-665.
4. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, et al. (2008) Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372: 1881-1893.
5. Rolland M, Tovanabutra S, deCamp AC, Frahm N, Gilbert PB, et al. (2011) Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nature medicine 17: 366-371.
6. Janes H, Frahm N, DeCamp A, Rolland M, Gabriel E, et al. (2012) MRKAd5 HIV-1 Gag/Pol/Nef vaccine-induced T-cell responses inadequately predict distance of breakthrough HIV-1 sequences to the vaccine or viral load. PLoS One 7: e43396.
7. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, et al. (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361: 2209-2220.
8. Rolland M, Nickle DC, Mullins JI (2007) HIV-1 Group M Conserved Elements Vaccine. PLoS Pathogens 3: e157.
9. Altfeld M, Allen TM (2006) Hitting HIV where it hurts: an alternative approach to HIV vaccine design. Trends Immunol 27(11): 504-510. (Pubitemid 44515162)
10. Létourneau S, Im E-J, Mashishi T, Brereton C, Bridgeman A, et al. (2007) Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLoS ONE 2: e984.
11. Yusim K, Kesmir C, Gaschen B, Addo MM, Altfeld M, et al. (2002) Clustering patterns of cytotoxic T-lymphocyte epitopes in human immunodeficiency virus type 1 (HIV-1) proteins reveal imprints of immune evasion on HIV-1 global variation. J Virol 76: 8757-8768. (Pubitemid 34864071)
12. Allen TM, Altfeld M, Geer SC, Kalife ET, Moore C, et al. (2005) Selective escape from CD8+ T-cell responses represents a major driving force of human immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals constraints on HIV-1 evolution. J Virol 79: 13239-13249. (Pubitemid 41508139)
13. Jones NA, Wei X, Flower DR, Wong M, Michor F, et al. (2004) Determinants of human immunodeficiency virus type 1 escape from the primary CD8+ cytotoxic T lymphocyte response. J Exp Med 200: 1243-1256. (Pubitemid 39552566)
14. Liu Y, McNevin J, Zhao H, Tebit DM, Troyer RM, et al. (2007) Evolution of human immunodeficiency virus type 1 cytotoxic T-lymphocyte epitopes: fitness-balanced escape. J Virol 81: 12179-12188. (Pubitemid 350085833)
15. Crawford H, Prado JG, Leslie A, Hue S, Honeyborne I, et al. (2007) Compensatory Mutation Partially Restores Fitness And Delays Reversion Of Escape Mutation Within The Immunodominant Hla-B*5703-Restricted Gag Epitope In Chronic Hiv-1 Infection. J Virol 81: 8346-8351. (Pubitemid 47101520)
16. Cahall DL, Youmans GP (1975) Conditions for production, and some characteristics, of mycobacterial growth inhibitory factor produced by spleen cells from mice immunized with viable cells of the attenuated H37Ra strain of Mycobacterium tuberculosis. Infect Immun 12: 833-840.
17. Troyer RM, McNevin J, Liu Y, Zhang SC, Krizan RW, et al. (2009) Variable fitness impact of HIV-1 escape mutations to cytotoxic T lymphocyte (CTL) response. PLoS Pathog 5: e1000365.
18. Schneidewind A, Brockman MA, Yang R, Adam RI, Li B, et al. (2007) Escape from the Dominant HLA-B27-Restricted Cytotoxic T-Lymphocyte Response in Gag Is Associated with a Dramatic Reduction in Human Immunodeficiency Virus Type 1 Replication. J Virol 81: 12382-12393. (Pubitemid 350085852)
19. Liu Y, Mullins JI (2012) A sensitive real-time PCR based assay to estimate the impact of amino acid substitutions on the competitive replication fitness of human immunodeficiency virus type 1 in cell culture. Journal of Virological Methods: In Press.
20. Liu Y, McNevin J, Cao J, Zhao H, Genowati I, et al. (2006) Selection on the human immunodeficiency virus type 1 proteome following primary infection. J Virol 80: 9519-9529. (Pubitemid 44435628)
21. Stekler J, Collier AC (2004) Primary HIV Infection. Curr HIV/AIDS Rep 1: 68-73.
22. Herbeck JT, Rolland M, Liu Y, McLaughlin S, McNevin J, et al. (2011) Demographic processes affect HIV-1 evolution in primary infection before the onset of selective processes. Journal of virology 85: 7523-7534.
23. Bryksin AV, Matsumura I (2010) Overlap extension PCR cloning: a simple and reliable way to create recombinant plasmids. Biotechniques 48: 463-465.
24. Sarkar G, Sommer SS (1990) The "megaprimer" method of site-directed mutagenesis. Biotechniques 8: 404-407.
25. Stech J, Stech O, Herwig A, Altmeppen H, Hundt J, et al. (2008) Rapid and reliable universal cloning of influenza A virus genes by target-primed plasmid amplification. Nucleic Acids Res 36: e139.
26. DuBridge RB, Tang P, Hsia HC, Leong PM, Miller JH, et al. (1987) Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. Mol Cell Biol 7: 379-387. (Pubitemid 17230421)
27. McClure J, van't Wout AB, Tran T, Mittler JE (2007) Granulocyte-monocyte colony-stimulating factor upregulates HIV-1 replication in monocyte-derived macrophages cultured at low density. J Acquir Immune Defic Syndr 44: 254-261. (Pubitemid 46328340)
28. Reed LJ, Muench H (1938) A simple method of estimating fifty percent endpoints. Am J Hyg 27: 493-497.
29. Lanxon-Cookson EC, Swain JV, Manocheewa S, Smith RA, Maust B, et al. (2013) Factors affecting relative fitness measurements in pairwise competition assays of human immunodeficiency viruses. J Virol Methods 194: 7-13.
30. Wu H, Huang Y, Dykes C, Liu D, Ma J, et al. (2006) Modeling and estimation of replication fitness of human immunodeficiency virus type 1 in vitro experiments by using a growth competition assay. J Virol 80: 2380-2389. (Pubitemid 43271543)
31. Ma J, Dykes C, Wu T, Huang Y, Demeter L, et al. (2010) vFitness: a web-based computing tool for improving estimation of in vitro HIV-1 fitness experiments. BMC Bioinformatics 11: 261.
32. Rose PP, Korber BT (2000) Detecting hypermutations in viral sequences with an emphasis on G -> A hypermutation. Bioinformatics 16: 400-401. (Pubitemid 30417085)
33. Llano A, Frahm N, Brander C (2009) How to optimally define optimal cytotoxic T lymphocyte epitopes in HIV Infection? HIV Molecular Immunology 2009: 3-24.
34. Liu Y, McNevin JP, Holte S, McElrath MJ, Mullins JI (2011) Dynamics of viral evolution and CTL responses in HIV-1 infection. PLoS ONE 6: e15639.
35. Koval CE, Dykes C, Wang J, Demeter LM (2006) Relative replication fitness of efavirenz-resistant mutants of HIV-1: correlation with frequency during clinical therapy and evidence of compensation for the reduced fitness of K103N + L100I by the nucleoside resistance mutation L74V. Virology 353: 184-192. (Pubitemid 44291782)
36. Brockman MA, Schneidewind A, Lahaie M, Schmidt A, Miura T, et al. (2007) Escape and Compensation from Early HLA-B57-Mediated Cytotoxic T-Lymphocyte Pressure on Human Immunodeficiency Virus Type 1 Gag Alter Capsid Interactions with Cyclophilin A. J Virol 81: 12608-12618. (Pubitemid 350085874)
37. Yoo S, Myszka DG, Yeh C, McMurray M, Hill CP, et al. (1997) Molecular recognition in the HIV-1 capsid/cyclophilin A complex. J Mol Biol 269: 780-795. (Pubitemid 27280846)
38. von Schwedler UK, Stray KM, Garrus JE, Sundquist WI (2003) Functional surfaces of the human immunodeficiency virus type 1 capsid protein. J Virol 77: 5439-5450. (Pubitemid 36460957)
39. Gamble TR, Yoo S, Vajdos FF, von Schwedler UK, Worthylake DK, et al. (1997) Structure of the carboxyl-terminal dimerization domain of the HIV-1 capsid protein. Science 278: 849-853. (Pubitemid 27467920)
40. Patarca R, Haseltine WA (1985) A major retroviral core protein related to EPA and TIMP. Nature 318: 390.
41. Wills JW, Craven R (1991) Form, function, and use of retroviral gag proteins. AIDS 5: 639-654.
42. Hansen LJ, Chalker DL, Sandmeyer SB (1988) Ty3, a yeast retrotransposon associated with tRNA genes, has homology to animal retroviruses. Mol Cell Biol 8: 5245-5256.